Clarity Pharmaceuticals Ltd

ASX:CU6 Stock Report

Market Cap: AU$1.8b

Clarity Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Michelle Parker

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.3%
Management average tenure2.6yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Sep 23
We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

CEO

Michelle Parker

less than a year

Tenure

Ms. Michelle Parker is Executive Director of Clarity Pharmaceuticals Ltd from August 2024 and is its Chief Executive Officer and MD. Ms. Parker joined the Clarity Pharmaceuticals Ltd in June 2018. She serv...


Leadership Team

NamePositionTenureCompensationOwnership
Alan Taylor
Executive Chairman11yrsAU$1.22m4.9%
A$ 89.1m
David Green
Chief Financial Officer2.6yrsAU$273.61kno data
Colin Biggin
COO & Non-Independent Executive Directorless than a yearAU$1.02m1.35%
A$ 24.6m
Michelle Parker
CEO, MD & Executive Directorno datano data0.34%
A$ 6.1m
Matthew Harris
Chief Scientific Officerno dataAU$241.43k1.89%
A$ 34.5m
Lisa Sadetskaya
Director of Corporate Communications.no datano datano data
Mary Bennett
Head of People & Cultureno datano datano data
Shaemus Gleason
Executive Vice President of Operationsno datano datano data
Othon Gervasio
Chief Medical Officerno datano datano data
Robert Vickery
Company Secretaryno dataAU$268.69kno data

2.6yrs

Average Tenure

Experienced Management: CU6's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alan Taylor
Executive Chairman11yrsAU$1.22m4.9%
A$ 89.1m
Colin Biggin
COO & Non-Independent Executive Director5.1yrsAU$1.02m1.35%
A$ 24.6m
Michelle Parker
CEO, MD & Executive Directorless than a yearno data0.34%
A$ 6.1m
Christopher Roberts
Non-Executive Director8.7yrsAU$86.88k5.66%
A$ 102.9m
Thomas Ramdahl
Non-Executive Director5.7yrsAU$86.88k0.22%
A$ 4.1m
Neal Shore
Member of Scientific Advisory Board2.5yrsno datano data
Rosanne Robinson
Lead Independent Non-Executive Director14.1yrsAU$95.72k0.056%
A$ 1.0m
Jason Lewis
Member of Scientific Advisory Boardno datano datano data
Oliver Sartor
Member of Scientific Advisory Board4.7yrsno datano data
Paul Donnelly
Member of Scientific Advisory Boardno datano datano data
Andrei Iagaru
Member of Scientific Advisory Board2.6yrsno datano data
Louise Emmett
Member of Scientific Advisory Board2.4yrsno datano data

4.9yrs

Average Tenure

Experienced Board: CU6's board of directors are considered experienced (4.9 years average tenure).